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Introduction
Recent advances in the treatment of inﬂ  ammatory 
arthritides – which include rheumatoid arthritis (RA), 
ankylosing spondylitis (AS), and psoriatic arthritis 
(PsA) – have resulted from greater understanding of the 
pathogenesis of these diseases. Cellular-level and 
molecular-level research has revealed that these diseases 
share some common mechanisms [1]. Most critically, the 
proinﬂ   ammatory mechanisms of these diseases are 
associated with progressive joint destruction early in the 
disease course [2].
In the present article, we review insights into the 
management of inﬂ  ammatory arthritides that have been 
gained from experience with the ﬁ  rst generation of TNF 
inhibitors. We then discuss newer biologic agents as well 
as novel targeted small molecules that act on signalling 
pathways, all of which are expanding our knowledge of 
inﬂ   ammatory arthritides and providing more compre-
hen  sive management options.
Lessons learned from TNF inhibitors
Th   e development of biologic agents that selectively block 
cytokines has provided a major advance in the treatment 
of inﬂ  ammatory arthritides [3,4]. TNF is a proinﬂ  am-
matory cytokine known to be present in higher concen-
trations in patients with RA, AS, and PsA. Th  is  cytokine 
plays a dominant role in the inﬂ  ammatory  cascade 
under  lying various inﬂ  ammatory disorders [5-8]. TNF is 
both an auto  crine stimulator and a potent paracrine 
inducer of other inﬂ  ammatory cytokines, including the 
interleukin family [8].
To date, three TNF-targeting agents have dominated 
the biologic management of RA, AS, and PsA. Etanercept, 
a dimeric fusion protein, consists of the extracellular 
portion of the human p75 TNF receptor linked to the Fc 
region of human IgG1 [9,10]. Inﬂ   iximab, a chimeric 
human–murine monoclonal antibody, binds to TNF and 
consists of human constant and murine variable regions. 
Adalimumab is a recombinant human monoclonal anti-
body speciﬁ   c to TNF [11,12]. All three anti-TNF 
therapies have well-demonstrated eﬃ   cacy in RA, AS, and 
PsA [9,11,12]. Th   is section focuses on these three agents, 
for which the most data exist.
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into daily practice.
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treatment with any one of these antagonists in combi  na-
tion with methotrexate (MTX) leads to low disease 
activity or remission in a considerable percentage of 
patients [13-15]. TNF inhibitors can potentially prevent 
radiological progression and thereby prevent disability. 
However, the pharmacokinetics and binding proﬁ  les of 
these agents are diﬀ  erent [1]. Nevertheless, randomised 
clinical trials (RCTs) in RA strongly suggest that all three 
TNF inhibitors eﬀ  ectively reduce signs and symptoms, 
improve physical function, and inhibit progression of 
structural damage.
According to the manufacturers, an estimated 1,136,000 
patients have been exposed to inﬂ  iximab, 500,000 patients 
to etanercept, and 370,000 patients to adalimumab 
worldwide since these products became commercially 
available. Th   e regular monitoring requirements for TNF 
inhibitors are less stringent than those required for many 
conventional disease-modifying antirheumatic drugs 
(DMARDs). TNF inhibitors are commonly used in 
combination with conventional DMARDs, however, so 
most patients will still require monitoring.
Safety
Bacterial infections, including sepsis and pneumonia, 
invasive fungal infections, and other opportunistic infec-
tions (for example, pneumocystosis, candidiasis, listeriosis, 
aspergillosis), have been reported with the use of TNF 
inhibitors [9,11,12]. Reactivation of latent tuberculosis 
following treatment has led to the introduction of pre-
initiation screening procedures, which have successfully 
reduced the number of reported cases [16,17]. Th   e risk of 
reactivation of latent tuberculosis is, of course, dependent 
on the incidence of latent infection and is associated with 
all TNF inhibitors [18,19]. Some registry data, however, 
suggest that the risk may be lower with etanercept 
[20-22]. In RA patients, risk factors include active long-
standing disease, age, country of origin, history of 
exposure to a person with tuberculosis, concomitant use 
of immunomodulators, and disease activity [23]. 
Physicians should remain alert to the development of 
symptoms related to tuberculosis or other infections.
Owing to adverse eﬀ  ects observed during clinical trials, 
patients with congestive heart failure should be closely 
monitored if they are receiving TNF inhibitors [9,11,12]. 
Other rarely reported conditions possibly related to use 
of TNF inhibitors include demyelinating disease, seizures, 
aplastic anaemia, pancytopaenia, and drug-induced lupus 
[9,11,12]. Physicians should remain vigilant for the 
development of these conditions [16].
Formation of antibodies
Th  e formation of antibodies to biologic agents is a 
signiﬁ  cant issue because antibodies have the potential to 
reduce the eﬃ   cacy of the agent or to cause adverse events 
[10]. All three TNF inhibitors have been associated with 
the development of antibodies, although etanercept does 
not appear to generate neutralising antibodies [9-12, 
24-26]. Th   e use of MTX in combination with TNF inhibi-
tors appears to reduce the incidence of antibody for  ma-
tion [10-12,24].
In a cohort study of 53 patients receiving etanercept for 
AS without MTX, mean etanercept levels in responders 
and nonresponders at 12 and 24 weeks were similar, and 
no antibodies to etanercept were detected [27]. No 
correlation was found among etanercept levels, formation 
of antibodies to etanercept, and clinical response. Con-
versely, in a 54-week cohort study of 38 patients receiving 
inﬂ  iximab for AS, detection of antibodies to inﬂ  iximab 
was associated with undetectable serum trough inﬂ  ixi-
mab levels and reduced response to treat  ment [28].
Shared mechanisms
A look at the cellular and molecular levels of diseases in 
rheumatology demonstrates that such diseases share 
common mechanisms and may be more closely related 
than previously recognised. Rigorous studies have 
examined the mechanisms of action of the anti-TNF 
inhibitors, particularly inﬂ  iximab and etanercept; however, 
many questions remain unresolved [1]. For example, 
although both inﬂ  iximab and etanercept are useful in the 
treatment of peripheral arthritis and AS, there appear to 
be diﬀ  erences in their eﬀ  ects at the cellular level [29,30]. 
Moreover, while their actions in AS have yet to be fully 
elucidated, the long-lasting suppression of T-cell function 
apparent during treatment with inﬂ  iximab suggests that 
neutralisation of soluble TNF cannot be the only 
mechanism [29]. Possible mechanisms generally fall into 
two categories: those mediated by blockade of the TNF 
receptor, and those mediated by induction of trans-
membrane TNF. Several mechanisms probably act 
simul taneously.
To what extent various mechanisms contribute to drug 
eﬃ   cacy remains an open question. All of the anti-TNF 
agents bind to transmembrane TNF and could theo-
retically induce both complement-dependent cytotoxicity 
and antibody-dependent cellular cytotoxicity, although at 
lower levels for etanercept compared with the anti-TNF 
agents inﬂ   iximab and adalimumab [1]. Th  e roles of 
apoptosis and inﬂ   ammation reversal for reducing 
cellularity in rheumatoid synovial tissue during anti-TNF 
therapy are unclear [1]. A study by Wijbrandts and 
colleagues analysed apoptosis in peripheral blood and 
synovial tissue within 24 hours of treatment with 
inﬂ  iximab in patients with RA. Th  ere were no signs of 
apoptosis induction in peripheral blood monocytes or 
lymphocytes after inﬂ   iximab treatment. Th  ese results 
support the view that the rapid decrease in synovial 
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cannot be explained by apoptosis induction at the site of 
inﬂ  ammation [31].
Routes of administration
Th   e TNF inhibitors all require parenteral administration, 
either intravenously (inﬂ   iximab) or via subcutaneous 
injection (etanercept, adalimumab) [4]. Th   e availability of 
diﬀ  erent formulations allows tailoring of treatment to the 
individual and ensures that the patient is receiving 
maximal beneﬁ  t with minimal negative impact on their 
quality of life. Although some patients appreciate the 
control oﬀ  ered by self-administration of subcutaneous 
injections, others do not like to self-inject. Intravenous 
drugs can be inconvenient because of the need for regular 
hospital visits, but some patients desire regular contact 
with medical professionals. Th  e decision on whether to 
use an intravenous or subcutaneous product should be 
based on the clinician’s and patient’s goals for treatment.
Intravenous administration allows high serum concen-
trations to be rapidly achieved, and therefore oﬀ  ers the 
potential for fast, complete suppression of inﬂ  ammation 
[32,33]. Rapid improvement in signs and symptoms has 
been observed following the usual clinical dose of 
inﬂ  iximab (3 mg/kg) in RA patients [34]. Within 48 hours 
of administration, patients experienced signiﬁ  cant 
improvements in the mean duration of morning stiﬀ  ness, 
patient assessment of pain, physician global assessment 
of arthritis, and patient global assessment of arthritis 
compared with baseline measurements. Studies using a 
high-dose infu  sion of inﬂ   iximab (10 mg/kg) in RA 
patients have shown signiﬁ  cant reductions in C-reactive 
protein levels [35,36], improvements in Disease Activity 
Score (DAS) and American College of Rheumatology 
(ACR) response [37], and signiﬁ  cant re  duc  tions in bone 
resorption as measured by β-CrossLaps, a predictor of 
annual bone loss in RA, as soon as 24 hours post infusion 
[37]. Th  e beneﬁ   ts of higher doses, however, must be 
weighed against accompanying increases in side eﬀ  ects. 
Additionally, inﬂ   iximab therapy has demonstrated a 
reduction in the number of inﬂ  ammatory cells, including 
intimal and sublining macrophages, T cells, and plasma 
cells, in rheumatoid synovial tissue as soon as 48 hours 
after initiation of treatment [33]. Although unlicensed, 
intravenous administration of adalimumab also has 
demon  strated a rapid onset of clinical eﬀ  ect  [38]. 
Whether intravenous administration of TNF antagonists 
has a faster eﬀ  ect than subcutaneous administration is 
not known presently, as no direct comparisons have been 
published.
Subcutaneous agents may be appropriate for and 
preferred by some patients. Although drug absorption 
into the bloodstream is slower and a delay of several days 
is possible before maximal concentrations are reached, 
desired outcomes can be achieved. While a rapid onset of 
eﬀ   ect for intravenous administration has been estab-
lished, there is on average no clear-cut diﬀ  erence in long-
term overall eﬃ     cacy outcomes between subcutaneous 
and intravenous administration.
Unmet needs in biologic therapy with TNF inhibitors
Although TNF inhibitors are currently the gold standard 
of biologics for patients with inﬂ  ammatory arthritides, 
there are still a number of outstanding questions 
regarding how to gain the maximum beneﬁ  t from these 
agents. Th  e most recent ACR guidance stating that 
patients with early RA are not candidates for biologic 
therapy [18] is debatable. Th  ere are convincing data 
indicating that the use of biologics early in the course of 
the disease can be highly eﬃ   cacious  and  may  induce 
clinical remission in a certain percentage of patients 
[13,15,39-41]. Additional data may spur modiﬁ  cation of 
guidelines and practice for those early RA patients who 
do not respond suﬃ   ciently to conventional treatment. Of 
importance, a well-deﬁ   ned referral pathway within 
health  care systems is needed to identify patients early in 
the course of the disease. Also, family physicians and 
other healthcare professionals must be educated about 
the early symptoms of inﬂ  ammatory arthritides, with an 
emphasis on the importance of early referral to 
rheumatologists for diagnosis and treatment [42].
Likewise, additional studies are needed to determine 
whether patients with co-morbidities or those taking 
concurrent medications require monitoring for speciﬁ  c 
toxicities [4]. Several registries have reported a high 
prevalence of co-morbid conditions in RA patients who 
are commencing biologic therapy in routine practice 
[43,44]. Oldroyd and colleagues compared 354 patients 
with AS from the Australian Rheumatology Association 
Database who were commencing biologic therapy with 
more than 1,000 enrolees from four RCTs involving 
biologic therapy. At baseline, patients from the Australian 
Rheumatology Association Database – considered 
representative of the general population seeking clinical 
care – were found to have much higher levels of co-
morbidity than the RCT subjects, as well as signiﬁ  cantly 
greater disease activity. Th  ese ﬁ  ndings have important 
implications for patient monitoring [45].
In a broader sense, RA trial inclusion criteria may need 
to be less restrictive [46]. A comparison of 546 RA 
patients from the Dutch Rheumatoid Arthritis Monitor-
ing registry with 1,223 RA patients from 11 RCTs showed 
much greater disease activity at baseline in RCT enrolees 
[47]. Th  e eﬃ   cacy of TNF-blocking agents was lower in 
Dutch Rheumatoid Arthritis Monitoring registrants. For 
example, in 10 of the 11 comparisons, the ACR 20% 
improvement criteria (ACR20) response rate was lower 
in the registry cohort (again, representative of daily 
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ence was signiﬁ  cant in ﬁ  ve of the 11 comparisons. Th  ese 
data indicate a smaller, real-world eﬀ   ect of anti-TNF 
treat  ment than the eﬀ  ect seen in trials. Th  e  discrepancy 
may be due to continued use of co-medication and 
selection toward greater disease activity in RCTs.
Zink and colleagues obtained similar results during 
their comparison of 1,458 patients from the Rheumatoid 
Arthritis Observation of Biologic Th  erapy registry with 
data from ﬁ   ve major RCTs that led to approval of 
biologics for RA. Only 21 to 33% of Rheumatoid Arthritis 
Observation of Biologic Th   erapy registrants would have 
been eligible for the trials, and this ineligible group 
demonstrated lower TNF inhibitor response rates than 
RCT enrolees who received biologic therapy. Th  e  investi-
gators concluded that observational cohort studies, 
which include a full spectrum of patients (for example, 
with various co-morbidities, taking assorted concomitant 
medications), are essential to complement RCT data [46]. 
A study of 417 RA patients from the Danish Database for 
Biological Th  erapies in Rheumatology further supports 
these clinical practice data. In the majority of these 
routine care patients, TNF antagonists were not success-
ful in controlling disease, although they did achieve 
moderate overall success in controlling clinical inﬂ  amma-
tion [48]. Clearly, a bridge is needed between trial results 
and real-world results.
Some studies have hypothesised that TNF inhibitors 
may have the potential to repair RA joint damage [49,50]. 
Th   e data to support this notion are currently negligible, 
however, and tools to measure and evaluate repair must 
be developed before in-depth investigations can be 
launched.
Potential for eff  ectiveness of TNF antagonists in early 
rheumatoid arthritis
In one study, a small number of patients experiencing RA 
symptoms for <12 months but considered to have a poor 
prognosis were randomised to receive either inﬂ  iximab 
plus MTX (n = 10) or placebo plus MTX (n = 10) for 
1  year [51]. Patients receiving inﬂ  iximab  experienced 
signiﬁ  cant improvements in all measures at the end of 
year 1 compared with those receiving placebo. Th  e 
inﬂ   iximab patients then received MTX alone for an 
additional year, and 70% of patients maintained the 
inﬂ   iximab responses, as measured by the C-reactive 
protein level, DAS in 28 joints (DAS28), and Health 
Assessment Questionnaire results [51].
van der Kooij and colleagues recently compared the 
clinical and radiological eﬃ   cacy of initial (n = 117) versus 
delayed (n = 67) treatment with inﬂ  iximab plus MTX in 
patients with early RA in a post hoc analysis of the BeSt 
study [52]. After 3 years of treatment, patients receiving 
initial inﬂ   iximab plus MTX demonstrated more 
improve  ment in functional ability over time, as measured 
by the Health Assessment Questionnaire, and were less 
likely to have radiological progression than patients 
treated with delayed inﬂ  iximab plus MTX. Th  ese  results 
suggest that initial treatment with a biologic-plus-
DMARD combi  nation in patients with recent-onset RA 
is more beneﬁ   cial than reserving such treatment for 
patients in whom traditional DMARDs have failed [52].
Th  e PREMIER study compared the eﬃ   cacy  of  early 
intervention with a combination of adalimumab and 
MTX versus either agent used alone as monotherapy in 
patients with early, aggressive RA [15]. Th   e primary end 
points in this 2-year, double-blind, controlled study 
(n = 799) were the percentage of patients in whom an 
ACR50 response was achieved and the mean change 
from baseline in the modiﬁ  ed Total Sharp Score, which 
assesses bone erosion and joint space narrowing on 
radiographs. Combination therapy was superior to 
adalimumab and MTX mono  therapy in all outcomes 
measured. At year 1, patients treated with combination 
therapy had a mean increase in Total Sharp Score of 1.3 
units compared with 3.0 units in those receiving 
adalimumab monotherapy (P = 0.002) and of 5.7 units in 
those receiving MTX monotherapy (P <0.001). At year 2, 
patients receiving combination therapy continued to 
have signiﬁ   cantly less radiographic progression (mean 
change 1.9 Sharp units) compared with those treated 
with either adalimumab (5.5 units) or MTX (10.4 units) 
monotherapy (P <0.001 for both comparisons). Although 
ACR responses were comparable in the two monotherapy 
arms, there was signiﬁ   cantly less progression in the 
adalimumab arm compared with the MTX arm at 
6 months (2.1 vs. 3.5), 1 year (3.0 vs. 5.7) and 2 years (5.5 
vs. 10.4) (P <0.001 for all comparisons). Th  is is another 
study suggesting the value of combination therapy in 
early RA [15].
Van der Heijde and colleagues have hypothesized that 
therapeutic intervention early in the disease course has a 
disproportionate beneﬁ   t on outcome if treatment is 
started early in the disease course [51]. Additionally, 
drug-free remis  sion may be a realistic goal in some 
patients with early RA. In the BeSt study, 19% of patients 
who received inﬂ   iximab plus MTX in a DAS-steered, 
tightly controlled manner were in drug-free remission at 
5 years, for a mean duration of 22 months. Inﬂ  iximab had 
been successfully discontinued in 58% of patients, while 
18% were still receiving combination therapy. Further-
more, compared with other treatment strategies, initial 
tem  porary treatment with inﬂ  iximab plus MTX resulted 
in signiﬁ  cantly better functional ability over 5 years [53]. 
Th  ese studies raise the possibility that if aggressive 
treatment to induce remission is instituted very early in 
the course of RA, more conservative management strate-
gies may be suﬃ   cient to maintain that remission.
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under discussion. For early-stage AS, one study showed 
inﬂ  iximab to be highly eﬃ   cacious in patients who were 
positive for HLA-B27, had recent-onset inﬂ  ammatory 
back pain, and had early sacroiliitis demonstrated by 
mag  netic resonance imaging [54].
Prediction and discontinuation of TNF antagonists
Additional unmet needs include: the ability to predict 
clinical response so that these drugs, which are expensive 
and have the potential for serious toxicity, can be targeted 
to patients who would most beneﬁ   t [55]; an under-
standing of acquired drug resistance to anti-TNF agents 
[56]; a full explanation for why patients with spondylo-
arthritis (a group of disorders that includes AS and PsA) 
have a 20% lower probability of discontinuing TNF 
antago  nists than patients with RA [57]; and an under-
standing of reasons for and predictors of discontinuation.
Relative to the ﬁ  rst point, the search for predictors of 
response is important in the context of personalised 
medicine, with the aim of increasing the percentage of 
patients exhibiting a robust response to a given treat-
ment. Wijbrandts and colleagues recently studied arthro-
scopic synovial tissue in 143 patients with active RA prior 
to initiating treatment with inﬂ  iximab [58]. Th  eir  analysis 
conﬁ  rmed that the baseline level of TNF expression may 
be a signiﬁ   cant predictor of response to anti-TNF 
therapy. At baseline, TNF expression in the intimal lining 
layer and synovial sublining was signiﬁ  cantly higher in 
responders than in nonresponders (clinical response 
determined at week 16) (P = 0.047 and P = 0.008, respec-
tively). Th   e number of macrophages, macrophage sub  sets, 
and T cells was also signiﬁ  cantly higher in respon  ders than 
in nonresponders [58]. Th   e relationship between synovial 
lymphocyte aggregates and the clinical response to 
inﬂ   iximab has also been studied in RA patients [59]. 
Synovial tissue biopsy samples were obtained from 97 
patients with active RA before initiation of inﬂ  iximab 
treatment. Lymphocyte aggregates were counted and 
graded for size, and logistic regression analysis identiﬁ  ed 
whether the presence of lymphocyte aggregates could 
predict clinical response at week 16. Th   e majority (57%) 
of RA synovial tissues contained lymphocyte aggregates. 
Additionally, aggregates were found in 67% of clinical 
responders compared with 38% of nonresponders. Th  e 
presence of aggregates at baseline was a highly signiﬁ  cant 
predictor of the clinical response to anti-TNF treatment 
(P = 0.008), demonstrating that RA patients with synovial 
lymphocyte aggregates may have a better response to 
inﬂ   iximab treatment than those with only diﬀ  use 
leucocyte inﬁ  ltration [59].
Relative to the fourth point, 21 to 35% of patients 
discontinue TNF-blocking agents within the ﬁ  rst  year 
[60]. Reasons for discontinuation appear to include lack 
of response, loss of response, development of intolerance, 
partial eﬃ   cacy, and adverse events [61,62]. Switching to a 
diﬀ   erent TNF inhibitor may be an option for some 
patients [63]. One limited study with 31 enrolees suggest-
ed that when etanercept is not eﬃ   cacious, inﬂ  iximab may 
oﬀ  er gains, and that when inﬂ  iximab fails due to adverse 
events, etanercept may allow continuation [61]. Another 
larger study (complete data for 197 patients) in RA 
suggested that a second TNF inhibitor may be eﬀ  ective 
after failure of the ﬁ  rst inhibitor, regardless of the reason 
for discontinuation of the ﬁ  rst agent [60]. Conceivably, 
eﬃ   cacy of a second TNF blocker may be lower in primary 
nonresponders to a ﬁ  rst TNF blocker (response being 
deﬁ  ned at 12 to 16 weeks after initiation of treatment). 
Switching to a diﬀ  erent mechanism of action and agent, 
such as rituximab, abatacept, or tocilizumab, is also an 
option (see below).
Identifying predictors of discontinuation would be 
valuable in managing disease and targeting therapies to 
patients most likely to beneﬁ   t. Currently, treatment 
choices are dominated by patient and physician prefer-
ence, side-eﬀ  ect proﬁ  les, and cost [64]. A cohort (n = 503) 
from the Brigham Rheumatoid Arthritis Sequen  tial Study 
was examined to identify clinical predictors associated 
with discontinuation of TNF inhi  bi  tors [64]. In this study, 
210 out of 503 patients (42%) discontinued therapy. 
Unfortunately, only 63 patients gave a reason; the 
investigators therefore shifted to a model-based analysis. 
Th   e results showed that higher risk of discontinuation was 
associated with prior use of another TNF agent. Lower risk 
of discontinuation was associated with longer disease 
duration, prior use of DMARDs, and longer MTX use.
More information is clearly needed with regard to 
individualising physician/patient decision-making about 
initiating anti-TNF agents, switching agents, and predict-
ing eﬃ   cacy and tolerability. Lowering the discontinua  tion 
rates is an important current goal.
Newly discovered mechanisms of action
More than 100 cytokines and chemokines have been 
identiﬁ  ed in the inﬂ  ammatory cascade associated with 
inﬂ   ammatory arthritides [1]. Although TNF is a key 
player in the proinﬂ   ammatory cytokine cascade, the 
complex interconnectivity and dynamics of cytokine 
biology mean that relationships between cytokines may 
be better visualised as a network within a cascade 
(Figure 1) [1,65].
Increased understanding of the pathophysiology of RA 
has led to the identiﬁ  cation of new therapeutic targets, 
including proinﬂ  ammatory cytokines, T cells and B cells, 
adhesion molecules, chemokines, and intracellular and 
extracellular signalling pathways. Th  e ﬁ  rst stage in the 
pathogenesis of RA is thought to be the activation of 
T cells via the T-cell receptor complex [66]. Th  e  second 
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cules on T cells and molecules on antigen-presenting 
cells, providing more targets for intervention [66]. 
Fibroblast-like synoviocytes are resident mesenchymal 
cells of the synovial joints and are increasingly recognised 
as key players in the pathogenesis of RA. Activation of 
ﬁ  broblast-like synoviocytes produces a broad array of cell 
surface and soluble mediators that help to recruit, retain, 
and activate cells of the immune system and resident 
joint cells, leading to the promotion of ongoing inﬂ  am-
mation and tissue destruction [67].
Cytokines such as IL-6, IL-12, IL-15, IL-17, IL-18, 
IL-21, IL-23, IL-33, and IFNγ provide potential targets 
for modulation [68], as do the signal transduction 
systems that follow the binding of cytokines to cell 
receptors, typically sequences of protein kinases such as 
mitogen-activated protein kinase [69]. Factors that 
modulate the transcription of genes following cytokine 
stimulation, such as NF-kB, provide more targets for 
modulation of cytokine pathways [70,71].
B cells are also important in the pathophysiology of 
RA, although their role is not as well understood as that 
of T cells. B cells produce autoantibodies, may act as 
antigen-presenting cells, secrete proinﬂ  ammatory cyto-
kines such as IL-6, and regulate T cells. In addition to 
possibly acting as antigen-presenting cells, B cells produce 
Figure 1. Relationships between cytokines. The cascade and network of cellular responses mediated by TNF common to infl  ammatory 
arthritides: rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis (Ps). Chond, chondrocyte; COX-2, cyclooxygenase-2; CRP, C-reactive protein; 
DC, dendritic cell; EC, endothelial cell; E-sel, E-selectin; GM-CSF, granulocyte–macrophage colony-stimulating factor; Hep, hepatoxyte; ICAM-1, 
intercellular adhesion molecule-1; IL, interleukin; INOS, inducible nitric oxide synthase; Mac, macrophage; MCP-1, monocyte chemotactic protein-1; 
MMP, matrix metalloproteinase; NO, nitric oxide; OC, osteoclast; OPG, osteoprotegerin; PGE2, prostaglandin E2; RANKL, receptor activator of NF-κB 
ligand; RANTES, regulated on activation normal T-cell expressed and secreted; ROI, reactive oxygen intermediates; SOD, superoxide dismutase; 
Treg supp, suppression of T regulatory cells; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor. Reproduced with 
permission from [1].
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inﬂ  ammation. Depletion of B cells is a logical therapeutic 
strategy that should provide a reduction in immuno-
inﬂ  ammatory components [72,73]. B-cell-related potential 
targets include B-lymphocyte stimulator and the 
proliferation-inducing ligand APRIL. Both assist the 
survival, proliferation, and antigen presentation of B cells. 
An exploratory phase IB trial of the recombinant fusion 
protein atacicept, which binds and neutralises B-lympho-
cyte stimulator and APRIL, was recently completed [74]. 
B cells also exhibit a regulatory capacity by controlling 
dendritic cell and T-cell function through cytokine 
production [75,76]. B-cell signalling pathways are emerg-
ing as potential therapeutic avenues. Targets include 
Bruton tyrosine kinase, which plays a key role in B-cell 
development and activation, and B-lymphocyte stimu-
lator, which is important to B-cell survival and matura-
tion [77].
Autoantibodies, such as anticitrullinated peptide 
antibodies and rheumatoid factor, serve as diagnostic and 
prognostic markers of RA. Th   eir presence in a variety of 
autoimmune diseases suggests that they may also be 
valuable therapeutic targets. For example, blockade of B-
cell traﬃ   cking may inhibit formation of autoantibodies 
[77]. Th   is is an area ripe for investigation.
Other areas of research include modulating comple-
ment activation to prevent the inﬂ  ux of inﬂ  ammatory 
cells into the synovium and inhibiting chemokines [78] to 
prevent the degradation of cartilage and bone [66]. Th  e 
receptor activator of NF-κB/receptor activator of NF-κB 
ligand pathway is also being targeted with the aim of 
regulating the formation and activation of osteoclasts 
[79].
Lastly, although it is still unclear whether patients who 
fail one TNF blocker should switch to another TNF 
blocker or to a drug with a diﬀ  erent mechanism of action, 
in RA in the recent past it has been common to try 
another TNF blocker after treatment with the ﬁ  rst TNF 
blocker has failed [80]. However, it is possible that TNF is 
not the crucial cytokine instigating RA in primary 
nonresponders (patients with no response 12 to 16 weeks 
after initiation of therapy) to anti-TNF therapy [58,80]. 
Initial evidence that primary nonresponders are less 
likely to respond to a second TNF blocker may accelerate 
the search for non-TNF targets [80]. Consistent with this 
notion, lower synovial TNF expression and fewer TNF-
producing inﬂ  ammatory cells are, on average, present in 
primary nonresponders [58]. Pharmacokinetics and 
pharmaco  genetics are expected to elucidate these 
concepts [81].
Advances in biologic therapy
Th   ere are many agents in development for the treatment 
of inﬂ  ammatory arthritides. Th   is is a highly competitive 
arena due to the complexity of interrelated pathways 
contributing to inﬂ  ammatory arthritis pathogenesis [66]. 
Establishing the exact role of diﬀ  erent treatments and 
identifying which patients will beneﬁ  t most from them 
are the challenges now facing rheumatologists.
Rituximab
Rituximab, a chimeric anti-CD20 monoclonal antibody, 
was the ﬁ  rst B-cell agent approved for treatment of RA 
[82]. Th  is antibody was approved in combination with 
MTX in the United States and Europe in 2006 for adult 
patients with, respectively, moderate to severe active RA 
or severe active RA, after the failure of at least one TNF 
inhibitor. Th   e agent targets B cells, rather than the entire 
immune system, and is administered by intravenous 
infusion to patients with an inadequate response to TNF 
inhibitors [83]. Rituximab has been shown to inhibit 
progression of structural damage in RA over 2 years, and 
continues to inhibit joint damage with long-term 
treatment [39,84].
In the event of inade  quate eﬃ     cacy with a TNF 
inhibitor, some have suggested that switching patients to 
rituximab is a more eﬀ  ective management strategy than 
switching to another TNF inhibitor [85]. A prospective 
cohort study of 318 RA patients found that when the 
motive for switching to rituximab was TNF inhibitor 
ineﬀ   ectiveness, disease improvement was signiﬁ  cantly 
better than with an alternative TNF inhibitor [85]. If the 
reason for switching is not lack of eﬃ   cacy (for example, 
adverse events, patient preference), there is no advantage 
in switching to rituximab [85].
Immunoglobulin levels have been found to be lower in 
patients receiving rituximab in the long term for RA [86]. 
An initial apparent trend toward higher rates of serious 
infection in this population may have been discounted by 
an open-label study of 1,039 RA patients [87]. Th  e  serious 
infection rate was 5.0 per 100 patient-years, similar to 
that for etanercept, inﬂ  iximab, and adalimumab (5.3 per 
100 patient-years) [88]. Th  ere also have been reports of 
psoriasis and PsA developing in RA patients receiving 
rituximab [89]; however, the same is true for TNF inhibi-
tors [90]. Th  e development of progressive multifocal 
leukoencephalopathy or hepatitis B reactivation during 
rituximab treatment for RA is very rare.
Abatacept
Abatacept is a T-cell co-stimulation modulator adminis-
tered by intravenous infusion. Th   e modulator is thought 
to prevent the activation of T lymphocytes, including 
naïve T cells [91,92]. Abatacept was approved in the 
United States and Europe in 2005 for treatment of RA in 
adult patients with an inadequate response to DMARDs 
or TNF inhibitors. In January 2010 it was approved in 
Europe for moderate-to-severe active polyarticular 
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older. Because abatacept was the ﬁ  rst therapy targeting 
the inhibition of co-stimulatory signals to prevent T-cell 
activation, its use in early disease [93] and in biologic-
naïve patients with active RA [94] has generated 
particular interest and investigation [91,95-97]. Th  ese 
data may support the use of abatacept in biologic-naïve 
patients with early disease who have had an inadequate 
response to MTX.
Th   e magnitude of abatacept’s eﬀ  ect appears to increase 
over time. According to the initial report of the Abatacept 
in Inadequate Responders to Methotrexate, Abatacept or 
Inﬂ  iximab versus Placebo, a Trial for Tolerability, Eﬃ   -
cacy, and Safety in Treating Rheumatoid Arthritis study, 
clinical response and disease activity were not only 
maintained from 6 to 12 months, but also appeared to 
improve [98]. Th  e report containing 2-year results is 
currently only in abstract form but shows that reduced 
disease activity was maintained with ongoing abatacept 
treatment [94,99]. Abatacept has also demonstrated an 
increasing and signiﬁ  cant degree of inhibition of struc-
tural damage progression in patients receiving treatment 
for 2 years [95]. Abatacept may have an increasing 
disease-modifying eﬀ  ect on structural damage over time 
in the majority of patients who respond to treatment. To 
date, this is a unique observation among biologic 
treatments for RA.
Th  e long-term eﬃ     cacy and safety of abatacept have 
been demonstrated over 5 years with a dose of 10 mg/kg 
[97]. In a long-term extension trial, abatacept was well 
tolerated and provided durable improvements in disease 
activity, with no unique safety events reported. Th  ese 
data, combined with relatively high retention rates, con-
ﬁ  rm that abatacept provides sustained clinical beneﬁ  ts in 
RA. Additionally, abatacept has been shown to provide 
clinical beneﬁ  ts in patients with RA who have previously 
failed TNF inhibitor treatment, regardless of the previous 
TNF inhibitor(s) used or the reason(s) for treatment 
failure [100]. Th  is ﬁ   nding suggests that switching to 
abata  cept may be a useful option for patients who fail 
TNF inhibitor treatment.
Tocilizumab
Tocilizumab is a humanised anti-IL-6-receptor mono-
clonal antibody administered by intravenous infusion. 
Th  is antibody inhibits signals through both membrane 
and soluble IL-6 receptors [101]. Tocilizumab has received 
approval in Europe and the United States (January 2009 
and 2010, respectively) for the treatment of moderate to 
severe RA in adult patients who have responded inade-
quately or have been intolerant to previous therapy with 
one or more DMARDs or TNF antagonists.
Tocilizumab used as monotherapy or in combination 
with MTX has demonstrated superiority over MTX 
mono  therapy in reducing disease activity in RA over 
24 weeks [102,103]. Furthermore, tocilizumab has resulted 
in signiﬁ  cant improvements compared with placebo in 
physical function, fatigue, and physical and mental health 
scores over 24 weeks in patients who fail to respond to 
conventional DMARD therapy alone [104]. Tocilizumab 
has also demonstrated eﬃ   cacy in RA patients who fail to 
achieve an adequate response with or became refractory 
to TNF inhibitors [105].
Th   ere is a close relationship between normalisation of 
serum IL-6 levels following treatment with tocilizumab 
and clinical remission. In the phase III SATORI trial, 
patients whose serum IL-6 levels became normal tended 
to achieve DAS28 remission. Normal IL-6 levels may 
therefore provide a good marker to identify patients who 
can stop tocilizumab treatment without the risk of ﬂ  aring 
[106,107].
In the 3-year extension of the SAMURAI study, 
patients with early RA treated with tocilizumab exhibited 
strongly suppressed radiographic progression [108]. 
Further  more, radiographic progression was more eﬀ  ec-
tively suppressed in patients who received tocilizumab at 
the start of the trial than in those who received 
conventional DMARDs at the start. Early introduction of 
tocilizumab treatment may therefore be more eﬀ  ective in 
preventing joint damage. Th  e LITHE study in 1,196 
patients who had inadequate responses to MTX further 
supports the potential for tocilizumab to suppress 
radiographic pro  gression [109]. Patients also demon-
strated improvements in physical function.
Tocilizumab has a well-characterised safety proﬁ  le, 
with infections being the most common adverse event in 
trials [101,109]. Safety data pooled from ﬁ  ve  pivotal 
tocilizumab studies demonstrate rates of serious infec-
tion of 3.5 per 100 patient-years for the 4 mg/kg dose and 
of 4.9 per 100 patient-years for the 8 mg/kg dose com-
pared with 3.4 per 100 patient-years for the comparator 
groups over a median 3.1 years’ treatment duration [109]. 
Physicians should also monitor for decreased neutrophil 
counts and increased lipid or liver enzyme levels, and 
manage appropriately [101,109].
Certolizumab pegol
Certolizumab is a pegylated Fab fragment of a humanised 
anti-TNF monoclonal antibody that neutralises the 
activity of TNF [66]. Certolizumab was approved for 
treatment of RA in combination with MTX in the United 
States and Europe in 2009. Th  e use of pegylation 
increases the half-life of the molecule and eliminates the 
chimeric Fc portion. It is therefore hoped that adding 
poly  ethylene glycol will produce a longer-lasting com-
pound with fewer side eﬀ  ects, although it remains to be 
established whether pegylation does indeed confer these 
advantages in clinical practice [66].
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every 4 weeks as monotherapy has demonstrated a rapid 
onset of response and reduction in RA disease activity as 
early as week 1 [110]. When used in combination with 
MTX, certolizumab (400 mg at baseline weeks 2 and 4, 
then 200 or 400 mg every 2 weeks) reduces radiographic 
progression compared with MTX alone over 1 year, and 
the diﬀ  erence is already signiﬁ  cant at 6 months [111].
Golimumab
Golimumab is a fully human anti-TNF IgG1 monoclonal 
antibody that targets and neutralises both the soluble and 
membrane-bound forms of TNF [66]. Golimumab was 
recently approved for monthly subcutaneous treatment 
of adults with RA, PsA, and AS. A randomised, double-
blind, placebo-controlled dose-ranging study compared 
subcutaneous injections of golimumab with placebo in 
patients with active RA despite treatment with MTX 
[112]. In this study, greater eﬃ   cacy was demonstrated for 
golimumab 50 mg every 4 weeks in addition to MTX 
compared with MTX plus placebo in terms of ACR 
responses. Furthermore, 20% of patients receiving 
golimu  mab achieved DAS28 remission at week 16, 
compared with only 5.7% (P = 0.074) of patients receiving 
MTX alone. Over a 52-week treatment period, all clinical 
responses achieved at week 16 were maintained and/or 
improved, and no unexpected safety issues were observed 
[112].
Th  ese results have been further conﬁ  rmed in a phase 
III study in patients with established RA and disease 
activity despite treatment with MTX monotherapy [113]. 
Additionally, golimumab demonstrated eﬃ   cacy  in 
patients with established RA who had previously received 
other TNF inhibitors and in MTX-naïve patients 
[114,115].
Eﬃ   cacy has also been demonstrated in patients with 
PsA and AS treated with golimumab [116], similar to that 
for currently available TNF inhibitors [117,118]. Further-
more, golimumab is capable of increasing function in 
patients with AS [118]. In PsA, golimumab has also 
demonstrated improvements in psoriatic skin and nail 
disease [116].
Ustekinumab
Ustekinumab is a human monoclonal antibody directed 
against the p40 subunit of IL-12/IL-23 that has demon-
strated eﬃ   cacy in PsA [119]. In a parallel-group crossover 
study involving 146 patients, a signiﬁ  cantly  higher 
proportion of ustekinumab-treated patients achieved a 
response using ACR criteria compared with placebo-
treated patients at week 12. Ustekinumab was approved 
in 2009 in both the United States and Europe for 
treatment of patients with moderate-to-severe plaque 
psoriasis. Ustekinumab has not been approved for PsA.
Kinase targets in development
Kinases such as Janus kinase 3 are intracellular molecules 
that play a pivotal role in signal transduction of inter-
leukins. CP-690550 is an oral Janus kinase inhibitor 
developed to interfere with these enzymes. In a recent 
study, 264 patients were randomised equally to receive 
placebo, 5 mg CP-690550, 15 mg CP-690550, or 30 mg 
CP-690550 twice daily for 6 weeks and were followed for 
an additional 6 weeks after treatment. Th  e primary 
eﬃ     cacy endpoint was the ACR20 response rate at 
6  weeks [120]. Response rates were 70.5%, 81.2%, and 
76.8%, respectively, in the groups receiving 5 mg, 15 mg, 
and 30 mg CP-690550 twice daily compared with 29.2% 
in the placebo group (P <0.001). Th   is study also assessed 
pain, physical functioning, and health status using 
100-mm visual analogue scales, the Health Assessment 
Questionnaire – Disability Index, and the self-
administered Short-Form 36 [121]. Treatment with CP-
690550 resulted in clinically meaningful and statistically 
signiﬁ  cant patient-reported improvements by week 1 of 
treatment. Th  e incidence of blood lipid elevations and 
neutropaenia is concerning, however, and much longer-
term studies are needed.
Also of interest are data indicating that spleen tyrosine 
kinase could serve as a novel and promising target for 
immune intervention in rheumatic diseases. R788, a 
novel and potent small-molecule spleen tyrosine kinase 
inhibitor, recently demonstrated the ability to ameliorate 
established diseases in lupus-prone NZB/NZW F1 mice 
and MRL/lpr mice, and also signiﬁ  cantly reduced clinical 
arthritis in collagen-2-induced arthritis models [122,123]. 
In a recent 12-week double-blind study, 142 patients with 
active RA despite MTX therapy received R788 at con-
current doses of 50 mg, 100 mg, or 150 mg twice daily; 47 
patients received MTX plus placebo [124]. Th  e  primary 
endpoint, an ACR20 response at week 12, was achieved 
by the majority of patients receiving 150 mg or 100 mg 
twice daily (72% vs. 65%; P <0.01). Around one-half of the 
patients achieved an ACR50 response (57% vs. 49%), and 
more than one-quarter of patients achieved an ACR70 
response (40% vs. 33%). Th   ese results suggest that spleen 
tyrosine kinase inhibition is worthy of more in-depth 
study.
Conclusion
New approaches to inﬂ  ammatory arthritides are challen-
ging the rheumatologist. Th   e advent of biologic therapies 
has revolutionised treatment and has allowed us to 
further inﬂ  uence the progression of these diseases as well 
as their symptoms. Development of the ﬁ  rst biologics, 
TNF inhibitors, expanded our knowledge of the patho-
genesis of inﬂ  ammatory conditions. As TNF inhibitors 
have been available to rheumatologists for more than a 
decade, a large body of data has accumulated regarding 
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distinct mechanism of action (rituximab, abatacept, and 
tocilizumab) have been approved. Numerous other 
targets within the inﬂ  ammatory cascade continue to be 
identiﬁ   ed, and biologic and nonbiologic agents to 
modulate/inhibit the associated pathways are either in 
the pipeline or have already been developed. Th  e  relative 
eﬃ   cacy of these agents remains to be established, and, in 
time, head-to-head trials will be required to determine 
the best treatment options for patients.
An international task force comprising more than 60 
rheumatology experts and a patient recently developed 
recommendations for achieving optimal therapeutic 
outcomes in RA. Using a Delphi-like procedure, the 
members discussed, amended, and voted on evidence 
derived from a systematic literature review as well as 
expert opinion. Th  e resulting initiative, called Treat-to-
Target, shares information and strategies in an eﬀ  ort to 
determine the best options for patients [125].
In the meantime, the prospect of preventing radio-
graphic damage has led to a re-evaluation of how patients 
with inﬂ  ammatory arthritides are managed, with early 
diagnosis and referral becoming increasingly important. 
Additionally, researchers are acknowledging speciﬁ  c 
subgroups of patients who are more likely to derive 
beneﬁ   t from certain treatments. Before oﬀ  ering  treat-
ment options, the rheumatologist needs to be able to 
identify patients who are likely to respond to a particular 
treatment. Th   is ability would allow optimal treatment to 
be initiated sooner, thereby potentially reducing the costs 
and the risks to patients and preventing radiological 
progression.
Th  e search continues for biomarkers and molecular 
networks that can help us better understand the variable 
response to targeted therapy. Today, the key challenge 
facing rheumatologists is how best to integrate the 
advanced therapies into daily practice.
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